Webinar: ASCO 2025 Updates

Join us on Friday, June 20, for an exclusive pre-recorded webinar with Dr. Yelena Janjigian, Chief Scientific Officer of DDF’s Scientific Medical Advisory Board and a leading expert in gastroesophageal oncology at Memorial Sloan Kettering Cancer Center.

In this webinar, Dr. Janjigian will announce the latest results from the groundbreaking Matterhorn trial, a global Phase III study evaluating the combination of durvalumab (Imfinzi) with FLOT chemotherapy in patients with resectable gastric and gastroesophageal junction (GEJ) cancers. This trial is expected to provide new insights into the potential of this combination therapy to improve patient outcomes.

Dr. Janjigian will share details on the trial’s findings, including the pathologic complete response (pCR) rates, event-free survival (EFS), and the global applicability of the results. Don’t miss this chance to hear firsthand from one of the foremost authorities in the field about this promising advancement in gastric cancer treatment.

Register now to secure your spot and stay informed about the future of cancer care!